# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Chardan Capital analyst Geulah Livshits reiterates Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and maintains $20 price target.
Canaccord Genuity analyst Whitney Ijem maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and lowers the price target fr...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and maintains $18 p...
Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $...
TN-401 AAV9-Based Gene Therapy Being Developed to Treat the Underlying Cause of PKP2-associated Arrhythmogenic Right Ventricula...
U.S. stocks were lower, with the Dow Jones index falling around 100 points on Friday. Shares of Blend Labs, Inc. (NASDAQ: BLN...
Highly selective Small Molecule HDAC6 Inhibitor Effectively Reversed Heart Failure and Improved Diastolic Heart Function Alone ...
Shares of Fluor Corporation (NYSE: FLR) fell during Tuesday’s session following fourth-quarter results.